| Autor: |
Kim, Jae Hoon, Hong, Jang Hee, Jung, Jin‐Gyu, Jung, Won Tae, Nam, Kyu‐Yeol, Roh, Jae Seok, Choi, Youn Woong, Bang, Junbae, Huh, Hyunwook, Lee, Hye J., Moon, JungHa, Kim, Jaehee, Sunwoo, Jung |
| Předmět: |
|
| Zdroj: |
Clinical Pharmacology in Drug Development; Aug2024, Vol. 13 Issue 8, p842-851, 10p |
| Abstrakt: |
The combined cilostazol and rosuvastatin therapy is frequently used for coronary artery disease treatment. This open‐label, 3 × 3 crossover clinical trial evaluated the pharmacokinetics and safety of a fixed‐dose combination (FDC) of cilostazol/rosuvastatin (200 + 20 mg) versus a concurrent administration of the separate components (SCs) under both fasted and fed conditions. Among 48 enrolled healthy adults, 38 completed the study. Participants were administered a single oral dose of cilostazol/rosuvastatin (200 + 20 mg), either as an FDC or SCs in a fasted state, or FDC in a fed state, in each period of the trial. Blood samples were taken up to 48 hours after dosing, and plasma concentrations were analyzed using validated liquid chromatography‐tandem mass spectrometry. The geometric mean ratios of FDC to SCs for area under the plasma concentration‐time curve from time zero to the last quantifiable concentration (AUClast) and maximum plasma concentration (Cmax) were 0.94/1.05 and 1.06/1.15 for cilostazol and rosuvastatin, respectively (AUClast/Cmax). Compared with that during fasting, fed‐state administration increased the AUClast and Cmax for cilostazol by approximately 72% and 160% and decreased these parameters for rosuvastatin by approximately 39% and 43%, respectively. To conclude, the FDC is bioequivalent to the SCs, with notable differences in pharmacokinetics when administered in a fed state. No significant safety differences were observed between the treatments. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text